<DOC>
	<DOCNO>NCT02194322</DOCNO>
	<brief_summary>The objective present study obtain information safety , tolerability pharmacokinetics BIBN 4096 BS single intranasal administration increase dos healthy male female volunteer</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics After Administration Increasing Dose BIBN 4096 BS Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<criteria>Participants healthy male female Age range 21 50 year Body Mass Index ( BMI ) within 18.5 29.9 kg/mÂ² ( BMI calculation : weight kilogram divide square height meter ) In accordance Good Clinical Practice ( GCP ) local legislation volunteer suppose give write informed consent prior admission study As part screening ( within 14 day drug administration ) , subject receive complete medical examination ( include blood pressure , pulse rate , medical history , documentation demographic , inclusion/exclusion criterion concomitant therapy ) well 12lead Electrocardiogram ( ECG ) rhinomanometry ( order familiarize subject method ; screen rhinomanometric value report ) . Moreover laboratory parameter ( include drug screening , HBs antigen ( HBsAg ) , anti Hepatitis B core ( HBc ) antibody , anti Hepatitis C Virus ( HCV ) antibodies Human immunodeficiency virus ( HIV ) test well pregnancy test female subject determine . Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least 1 month less ten halflives respective drug enrolment study ( except substitution therapy regard thyroid gland/or ovary ) Use drug might influence result trial within 1 week prior administration trial Participation another study investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke study day Alcohol abuse ( &gt; 60g/day ) Drug abuse Blood donation ( &gt; = 100 ml ) within four week prior administration trial Excessive physical activity within last week study Any laboratory value outside reference range clinical relevance For female subject : Pregnancy Positive pregnancy test No adequate contraception e.g . oral contraceptive , sterilization , intrauterine pessary ( IUP ) Inability maintain adequate contraception whole study period Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>